Vertex Pharmaceuticals Inc (VRTX) stock
Close on Nov 11, 2026Market cap $138.65BP/E 31.8Yield –
Vertex Pharmaceuticals Inc grew revenue 10.2% to $12.59B over the twelve months to Jun 30, 2026. Operating income rose 21.8% to $4.78B, moving the operating margin from 34.4% to 38.0%. Free cash flow was $3.80B, up 8.5% from a year earlier. At the latest close the market valued the company at $138.65B, 31.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $138.65B
- P/E ratio
- 31.8
- Price to sales
- 11.02
- Price to book
- 6.85
- Dividend yield
- –
- Free cash flow yield
- 2.74%
Fundamentals
- Revenue
- $12.59B
- Net income
- $4.41B
- EPS, diluted
- $17.18
- Free cash flow
- $3.80B
- Book value per share
- $79.34
- Diluted shares
- 255M
Trading
- Next earnings
- Feb 11, 2027 (estimated, during market hours)
- Previous close
- $547.89
- Open
- $543.96
- Day's range
- $535.46 – $548.67
- Volume
- 1,078,915
- Average volume (20 days)
- 1,644,771
- Index membership
- S&P 500, Nasdaq-100, Russell 1000, Russell 3000
- Beta (5 years)
- 0.53
- 52-week range
- $412.27 – $568.67
- RSI (14 days)
- 57.3
- Volatility (1 year)
- 29.6%
- Relative volume
- 0.82×
- WACC
- 7.5%
On 2 of our idea lists: Quality compounders, Mega-cap growers
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, QQQ, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | VRTX | S&P 500 | Difference | VRTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +7.2% | -2.4% | +9.7 pts | ||
| 3 months | +3.3% | -1.2% | +4.4 pts | ||
| Year to date | +20.7% | +12.3% | +8.4 pts | ||
| 1 year | +27.4% | +12.4% | +15.0 pts | ||
| 3 years | +46.4% | +78.8% | −32.4 pts | +13.5% | +21.4% |
| 5 years | +194.3% | +75.2% | +119.1 pts | +24.1% | +11.9% |
| 10 years | +494.6% | +311.1% | +183.5 pts | +19.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vertex Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
About Vertex Pharmaceuticals
Pharmaceutical Preparations
Vertex Pharmaceuticals Incorporated is a biotechnology company operating within the pharmaceuticals segment that focuses on discovering, developing, and commercializing innovative therapies. Its commercial portfolio and product pipeline feature treatments such as TRIKAFTA/KAFTRIO, ALYFTREK, CASGEVY, and JOURNAVX, alongside collaborative research and development programs. The company supplies its therapeutic products primarily to specialized wholesale distributors, retail pharmacy chains, and healthcare distributors, including McKesson Corporation, Accredo Health Group Inc., and LloydsPharmacy.
Company profile, executives and historyVertex Pharmaceuticals stock: common questions
What is Vertex Pharmaceuticals's stock price?
VRTX closed at $547.03 on Nov 11, 2026, down 0.16% on the day. Over the past 52 weeks it traded between $412.27 and $568.67.
What is Vertex Pharmaceuticals's market cap?
Vertex Pharmaceuticals was worth $138.65B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is VRTX's P/E ratio?
VRTX trades at 31.8 times earnings, based on diluted earnings per share of $17.18 over the twelve months to Jun 30, 2026.
How much revenue does Vertex Pharmaceuticals make?
Vertex Pharmaceuticals reported revenue of $12.59B for the twelve months to Jun 30, 2026, up 10.2% from a year earlier.
Does Vertex Pharmaceuticals pay a dividend?
No. Vertex Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Vertex Pharmaceuticals report earnings next?
Vertex Pharmaceuticals is expected to report Q4 FY2026 results on Feb 11, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has VRTX stock performed over the past year?
Including dividends, VRTX returned +27.4% over the past year, against +12.4% for the S&P 500.
How many VRTX shares are sold short?
5M shares were sold short at the latest FINRA report, 1.90% of the float, or 3.4 days of average trading volume.
Who are Vertex Pharmaceuticals's competitors?
Companies most similar to Vertex Pharmaceuticals by business, industry and size include REGN, VTRS, TEVA, ALNY, GMAB.
See a number that looks wrong?